Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009

Anaerobe

Volumn 17, Issue 4, 2011, Pages 147-151

  Snydman, D R ^a,b   Jacobus, N V ^a   McDermott, L A ^a   Golan, Y ^a   Goldstein, E J C ^d   Harrell, L ^e   Jenkins, S ^f   Newton, D ^g   Pierson, C ^g   Rosenblatt, J ^h   Venezia, R ⁱ   Gorbach, S L ^b   Queenan, A M ^j   Hecht, D W ^c  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d RM Alden Research Laboratory ^*  (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^j JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

Antibiotic resistance; Bacteroides; Carbapenem resistance

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOXITIN; CHLORAMPHENICOL; CLINDAMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES; BACTEROIDES FRAGILIS; CFIA GENE; CONTROLLED STUDY; GENETIC ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTEROIDES FRAGILIS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, MICROBIAL; GENES, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

BACTEROIDES; BACTEROIDES FRAGILIS;

EID: 80051947329     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2011.05.014     Document Type: Article

References (22)

1. Tally F.P., Snydman D.R., Gorbach S.L., Malamy M.H. Plasmid-mediated transferable resistance to clindamycin and erythromycin in Bacteroides fragilis. J Infect Dis 1979, 139:83-88.
2. Cuchural G., Jacobus N., Gorbach S.L., Tally F.P. A survey of Bacteroides susceptibility in the United States. J Antimicrob Chemother 1981, 8(Suppl. D):27-31.
3. Snydman D.R., Jacobus N.V., McDermott L.A., Supran S., Cuchural G.J., Finegold S., et al. Multicenter study of in-vitro susceptibility of Bacteroides fragilis group, 1995-1996, with comparison of resistance trends from 1990-1996. Antimicrob Agents & Chemother 1999, 43:2417-2422.
4. Golan Y., McDermott L.A., Jacobus N.V., Goldstein E.J.C., Finegold S., Harrell L.J., et al. Emergence of fluoroquinolone resistance among the Bacteroides species. J Antimicrob Chemother 2003, 52:208-213.
5. Liu C.-Y., Huang Y.-T., Liao C.H., Yen L.-C., Lin H.Y., Hsueh P.R. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008, 52:3161-3168.
6. Roh K.H., Kim S., Kim C.K., Yum J.H., Kim M.S., Yong D., et al. New cfiA variant and novel insertion sequence elements in carbapenem-resistant Bacteroides fragilis isolates from Korea. Diag Microbiol Infect Dis 2010, 66:343-348.
7. Hawser S.P., Hackel M., Hoban D.J. Antibiotic susceptibility profiles of European Bacteroides fragilis with reduced carbapenems susceptibility. J Antimicrob Chemother 2010, 803-804.
8. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJC, et al. Increasing resistance of carbapenems to Bacteroides fragilis and related species: a US survey, 2006 - 2008. In: Presented at the European Congress of clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, April 2010; 2010.
9. Jousimies-Somer H.R., Summanem P., Citron D.M., Baron E.J., Wexler H., Finegold S.M. Wadsworth - KTL anaerobic bacteriology manual 2002, Star Publishing Co., Belmont CA. 6th ed.
10. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. CLSI publication number M11-A7 2007, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, PA.
11. Snydman D.R., Jacobus N.V., McDermott L.A., Ruthazer R., Goldstein E.J.C., Finegold S.M., et al. National survey on the susceptibility of the Bacteroides fragilis group: report and analysis of trends from 1997 - 2000. Clin Infect Dis 2002, 35(Suppl. 1):S126-S134.
12. Snydman D.R., Jacobus N.V., McDermott L.A., Ruthazer R., Golan Y., Goldstein E.J., et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007, 51:1649-1655.
13. Kato N., Yamazoe K., Han C.-G., Ohtsubo E. New insertion sequence elements in the upstream region of cfiA in imipenem-resistant Bacteroides fragilis strains. Antimicrob Agents Chemother 2003, 47:979-985.
14. Wyeth Pharmaceutical. Tygacil™ [package insert] available at:. http://fda.gov/cder/foi/label/2005/0218211b1.pdf.
15. Sakamoto M., Benno Y. Reclassification of Bacteroides distasonis, Bacteroides goldsteinii and Bacteroides merdae as Parabacteroides distasonis gen.nov.comb.nov., Parabacteroides goldsteinii comb.nov. and Parabacteroides merdae comb.nov. Int J Syst Evol Microbiol 2006, 56:1599-1605.
16. Thompson J.S., Malamy M.H. Sequencing the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from Bacteroides fragilis TAL2480 reveals strong similarity between CfiA and Bacillus cereus β-lactamase II. J Bacteriol 1990, 172:2584-2593.
17. Soki J., Fodor E., Hecht D.W., Edwards R., Rotimi V.O., Kerekes I., et al. Molecular characterization of imipenem-resistant, cfiA-positive Bacteroides fragilis isolates from the USA, Hungary and Kuwait. J Med Microbiol 2004, 53:413-419.
18. Boente R.F., Ferreira L.Q., Falcao L.S., Miranda K.R., Guimaraes P.L.S., Santos-Filho J., et al. Detection of resistance genes and susceptibility patterns in Bacteroides and Parabacteroides strains. Anaerobe 2010, 16:190-194.
19. Snydman D.R., Jacobus N.V., McDermott L.A., Golan Y., Hecht D.W., Goldstein E.J.C., et al. Lessons learned from the anaerobe survey: historical perspectives and review of the most recent data 2005-2007. Clin Infect Dis 2010, 50:S26-S33.
20. Paula G.R., Falcao L.S., Antunes E.N., Avelar K.E., Reis F.N., Maluhy M.A., et al. Determinants of resistance in Bacteroides fragilis strains according to recent Brazilian profiles of antimicrobial susceptibility. Int J Antimicrob Agents 2004, 24:53-58.
21. Nguyen M.H., Yu V.L., Morris A.J., McDermott L.A., Wagener M.W., Harrell L., et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000, 30:870-876.
22. Rosenblatt J.E., Brook I. Clinical relevance of susceptibility testing of anaerobic bacteria. Clin Infect Dis 1993, 16(S4):S446-S448.